WO2005063170A3 - Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof - Google Patents

Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof Download PDF

Info

Publication number
WO2005063170A3
WO2005063170A3 PCT/JP2004/019846 JP2004019846W WO2005063170A3 WO 2005063170 A3 WO2005063170 A3 WO 2005063170A3 JP 2004019846 W JP2004019846 W JP 2004019846W WO 2005063170 A3 WO2005063170 A3 WO 2005063170A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
immunoregulatory agents
regulates
caveolin
tollip
Prior art date
Application number
PCT/JP2004/019846
Other languages
French (fr)
Other versions
WO2005063170A2 (en
Inventor
Chikao Morimoto
Kei Ohnuma
Original Assignee
Toudai Tlo Ltd
Chikao Morimoto
Kei Ohnuma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toudai Tlo Ltd, Chikao Morimoto, Kei Ohnuma filed Critical Toudai Tlo Ltd
Priority to EP04808195A priority Critical patent/EP1709450A2/en
Priority to US10/584,837 priority patent/US7704686B2/en
Priority to JP2006520586A priority patent/JP2007517491A/en
Priority to CA002551912A priority patent/CA2551912A1/en
Publication of WO2005063170A2 publication Critical patent/WO2005063170A2/en
Publication of WO2005063170A3 publication Critical patent/WO2005063170A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of identifying a substance that down-regulates or up-regulates an immune response and kits used for the identification methods. A method of this invention comprises detecting a substance that inhibits or enhances the interaction between CD26 and caveolin-1. Another method comprises detecting a substance that inhibits or enhances the interaction between caveolin-1 and Tollip. Still another method comprises detecting a substance that inhibits or enhances the interaction among caveolin-1, Tollip, and IRAK-1. The present invention also relates to immunoregulatory agents comprising a substance that down-regulates an immune response, such as siRNA against caveolin-1 or Tollip. The invention further provides immunoregulatory agents comprising a substance that up-regulates an immune response. These agents are useful for treating inflammatory diseases, autoimmune diseases, or other immune-mediated disorders.
PCT/JP2004/019846 2003-12-29 2004-12-28 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof WO2005063170A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04808195A EP1709450A2 (en) 2003-12-29 2004-12-28 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
US10/584,837 US7704686B2 (en) 2003-12-29 2004-12-28 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
JP2006520586A JP2007517491A (en) 2003-12-29 2004-12-28 Methods for identifying immunomodulators, immunomodulators, and uses thereof
CA002551912A CA2551912A1 (en) 2003-12-29 2004-12-28 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53272303P 2003-12-29 2003-12-29
US60/532,723 2003-12-29

Publications (2)

Publication Number Publication Date
WO2005063170A2 WO2005063170A2 (en) 2005-07-14
WO2005063170A3 true WO2005063170A3 (en) 2005-11-10

Family

ID=34738829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/019846 WO2005063170A2 (en) 2003-12-29 2004-12-28 Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof

Country Status (5)

Country Link
US (1) US7704686B2 (en)
EP (1) EP1709450A2 (en)
JP (1) JP2007517491A (en)
CA (1) CA2551912A1 (en)
WO (1) WO2005063170A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030469B2 (en) 2005-07-22 2011-10-04 Sbi Incubation Co., Ltd. Anti-CD26 antibodies and methods of use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008061505A (en) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc Method of screening medicine for amyotrophic lateral sclerosis
EP2544003A1 (en) * 2011-07-07 2013-01-09 CNIC, Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Caveolin-1 in tumor-associated fibroblasts as biomarker for tumor progression
WO2013025474A2 (en) * 2011-08-12 2013-02-21 The Texas A&M University System Compositions and methods for regulating neutrophil movement and neutrophil numbers in a body region
JP5959248B2 (en) * 2012-03-15 2016-08-02 オリンパス株式会社 Methods for detecting cell-cell interactions
JP2016069314A (en) * 2014-09-29 2016-05-09 学校法人順天堂 Immunosuppressant
RU2619643C1 (en) * 2015-12-10 2017-05-17 ФАНО России Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН) Pigas cell line containing stat-1 transcription factor binding site stable-integrated in genome
JP2017131191A (en) * 2016-01-29 2017-08-03 国立大学法人京都大学 Method for screening agent for preventing and/or treating disease
US20220096543A1 (en) * 2018-12-24 2022-03-31 Virgina Tech Intellectual Properties, Inc. Tollip deficient neutrophils and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274987C (en) * 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US7205409B2 (en) * 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 255, no. 1, 5 February 1999 (1999-02-05), pages 34 - 39, ISSN: 0006-291X *
BIOCHEMISTRY, vol. 42, no. 26, 8 July 2003 (2003-07-08), pages 7892 - 7903, ISSN: 0006-2960 *
BLOOD, vol. 102, no. 11, 16 November 2003 (2003-11-16), 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 06-09, 2003, pages 38a, ISSN: 0006-4971 *
BURNS K ET AL: "Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 2, no. 6, June 2000 (2000-06-01), pages 346 - 351, XP002304736, ISSN: 1465-7392 *
CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUL 2001, vol. 7, no. 7, July 2001 (2001-07-01), pages 2031 - 2040, ISSN: 1078-0432 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 12 July 2002 (2002-07-12), MARELLA MATHIEU ET AL: "Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release", XP002323163, Database accession no. PREV200200467964 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2003 (2003-11-16), CHRISTOPHERSON KENT W ET AL: "Suppression or deletion of CD26 (DPPIV) activity on donor cells greatly enhances the efficiency of mouse hematopoietic stem & progenitor cell homing and engraftment in vivo.", XP002323162, Database accession no. PREV200400180998 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989, MORIMOTO C ET AL: "1F7 A NOVEL CELL SURFACE MOLECULE INVOLVED IN HELPER FUNCTION OF CD4 CELLS", XP002323154, Database accession no. PREV199089038221 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 25 July 2003 (2003-07-25), CHO KYUNG A ET AL: "Senescent phenotype can be reversed by reduction of caveolin status.", XP002323161, Database accession no. PREV200300419061 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 5 February 1999 (1999-02-05), TRIGATTI BERNARDO L ET AL: "Identification of caveolin-1 as a fatty acid binding protein", XP002323157, Database accession no. PREV199900134226 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 8 December 1997 (1997-12-08), VOLPE FILIPPO ET AL: "The IL1 receptor accessory protein is responsible for the recruitment of the interleukin-1 receptor associated kinase to the IL1/IL1 receptor I complex", XP002323159, Database accession no. PREV199800046238 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 8 July 2003 (2003-07-08), ELLIOTT MICHAEL H ET AL: "Cholesterol-dependent association of caveolin-1 with the transducin alpha subunit in bovine photoreceptor rod outer segments: Disruption by cyclodextrin and guanosine 5'-O-(3-thiotriphosphate).", XP002323158, Database accession no. PREV200300450283 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), NOMURA RYUJI ET AL: "Tyrosine-phosphorylated caveolin-1: Immunolocalization and molecular characterization", XP002323160, Database accession no. PREV199900377056 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2003 (2003-03-01), SOONG GRACE ET AL: "Selective recruitment of toll like receptor components mediates airway epithelial responses to bacteria.", XP002323164, Database accession no. PREV200300295564 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 1992 (1992-02-01), TORIMOTO Y ET AL: "Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies.", XP002323156, Database accession no. NLM1371820 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2001 (2001-07-01), HO L ET AL: "In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.", XP002323155, Database accession no. NLM11448921 *
FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03-01), FASEB MEETING ON EXPERIMENTAL BIOLOGY: TRANSLATING THE GENOME; SAN DIEGO, CA, USA; APRIL 11-15, 2003, pages Abstract No. 405.5 URL - http://ww, ISSN: 0892-6638 *
FEBS LETTERS, vol. 419, no. 1, 8 December 1997 (1997-12-08), pages 41 - 44, ISSN: 0014-5793 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 28, 12 July 2002 (2002-07-12), pages 25457 - 25464, ISSN: 0021-9258 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 30, 25 July 2003 (2003-07-25), pages 27789 - 27795, ISSN: 0021-9258 *
JOURNAL OF IMMUNOLOGY, vol. 143, no. 11, 1989, pages 3430 - 3439, ISSN: 0022-1767 *
MARTIN MICHAEL U ET AL: "Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1592, no. 3, 11 November 2002 (2002-11-11), pages 265 - 280, XP002323152, ISSN: 0006-3002 *
MOLECULAR BIOLOGY OF THE CELL, vol. 10, no. 4, April 1999 (1999-04-01), pages 975 - 986, ISSN: 1059-1524 *
MOLECULAR IMMUNOLOGY. FEB 1992, vol. 29, no. 2, February 1992 (1992-02-01), pages 183 - 192, ISSN: 0161-5890 *
OHNUMA K ET AL: "Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2001, vol. 167, no. 12, 15 December 2001 (2001-12-15), pages 6745 - 6755, XP002323150, ISSN: 0022-1767 *
OHNUMA KEI ET AL: "CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 28 SEP 2004, vol. 101, no. 39, 28 September 2004 (2004-09-28), pages 14186 - 14191, XP002323153, ISSN: 0027-8424 *
SUNAGA NORIAKI ET AL: "RNAi-mediated knockdown of caveolin-1 and c-myc leads to growth inhibition of human tumor cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 192 - 193, XP002323151, ISSN: 0197-016X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030469B2 (en) 2005-07-22 2011-10-04 Sbi Incubation Co., Ltd. Anti-CD26 antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20070259824A1 (en) 2007-11-08
CA2551912A1 (en) 2005-07-14
US7704686B2 (en) 2010-04-27
WO2005063170A2 (en) 2005-07-14
JP2007517491A (en) 2007-07-05
EP1709450A2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
WO2003008622A3 (en) Exponential nucleic acid amplification using nicking endonucleases
WO2003046146A3 (en) Compositions and methods of selective nucleic acid isolation
WO2006110314A3 (en) Methods and compositions for depleting abundant rna transcripts
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2005014850A3 (en) Systems and methods for analyzing nucleic acid sequences
ATE419388T1 (en) NUCLEIC ACID ENRICHMENT
WO2005117938A3 (en) Methods of treating ocular conditions
WO2004052175A3 (en) Methods for rapid identification of pathogens in humans and animals
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
WO2003033732A3 (en) Real-time detection of dna amplification products
WO2002044339A3 (en) Nucleic acid amplification methods
WO2003033722A3 (en) Nucleic acid amplification methods
WO2006059247A3 (en) VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
WO2005063170A3 (en) Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
WO2004001065A3 (en) Exhaustive selection or rna aptamers against complex targets
GB2428042A (en) P gingivalis vaccine
WO2002054072A3 (en) Assay to determine efficacy of treatment for mycobacterial infection
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
WO2005076939A3 (en) Assay and method for diagnosing and treating alzheimer’s disease
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006520586

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2551912

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004808195

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004808195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10584837

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10584837

Country of ref document: US